ArticleEuropean journal of internal medicine2018
The "BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons" (BIOSPHERE) study: Rationale, design and methods.
Article in European journal of internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 54 citations in OpenAlex.
- Anthropometric Measurements for Predicting Low Appendicular Lean Mass Index for the Diagnosis of Sarcopenia: A Machine Learning Model.Journal of functional morphology and kinesiology · 2025Article
- Bibliometric and scientometric analysis on biomarkers and molecular mechanisms for physical frailty and sarcopenia.Frontiers in medicine · 2024Article
- Article
- Associations of Serum CXCL12α and CK Levels with Skeletal Muscle Mass in Older Adults.Journal of clinical medicine · 2023Article
- Amino Acid Profiles in Older Adults with Frailty: Secondary Analysis from MetaboFrail and BIOSPHERE Studies.Metabolites · 2023Article
- Circulating Inflammatory, Mitochondrial Dysfunction, and Senescence-Related Markers in Older Adults with Physical Frailty and Sarcopenia: A BIOSPHERE Exploratory Study.International journal of molecular sciences · 2022Article
- South Asian Working Action Group on SARCOpenia (SWAG-SARCO) - A consensus document.Osteoporosis and sarcopenia · 2022Review
- Physiological Systems in Promoting Frailty.Comprehensive Physiology · 2022Review
- Article
- Evidence-based recommendations for resistance and power training to prevent frailty in community-dwellers.Aging clinical and experimental research · 2021Review
- Cardiovascular risk and aging: the need for a more comprehensive understanding.Journal of geriatric cardiology : JGC · 2021Article
- The Role of Artificial Intelligence in Managing Multimorbidity and Cancer.Journal of personalized medicine · 2021Review
- Identification of biomarkers for physical frailty and sarcopenia through a new multi-marker approach: results from the BIOSPHERE study.GeroScience · 2021Article
- Cross-sectional associations among P3NP, HtrA, Hsp70, Apelin and sarcopenia in Taiwanese population.BMC geriatrics · 2021Article
- The Gut-Muscle Axis in Older Subjects with Low Muscle Mass and Performance: A Proof of Concept Study Exploring Fecal Microbiota Composition and Function with Shotgun Metagenomics Sequencing.International journal of molecular sciences · 2020Article
- Lean Mass Abnormalities in Heart Failure: The Role of Sarcopenia, Sarcopenic Obesity, and Cachexia.Current problems in cardiology · 2020Review
- Heart Failure-Induced Skeletal Muscle Wasting.Current heart failure reports · 2020Review
- Biomarkers of Physical Frailty and Sarcopenia: Coming up to the Place?International journal of molecular sciences · 2020Review
- Article
- A Specific Urinary Amino Acid Profile Characterizes People with Kidney Stones.Disease markers · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
Abstract
Sarcopenia, the progressive and generalised loss of muscle mass and strength/function, is a major health issue in older adults given its high prevalence and burdensome clinical implications. Over the years, this condition has been endorsed as a marker for discriminating biological from chronological age. However, the absence of a unified operational definition has hampered its full appreciation by healthcare providers, researchers and policy-makers. In addition to this unsolved debate, the complexity of musculoskeletal ageing represents a major challenge to the identification of clinically meaningful biomarkers. Here, we illustrate the advantages of biomarker discovery procedures in muscle ageing based on multivariate methodologies as an alternative approach to traditional single-marker strategies. The rationale, design and methods of the "BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons" (BIOSPHERE) study are described as an application of a multi-marker strategy for the development of biomarkers for the newly operationalised Physical Frailty & Sarcopenia condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.